联化科技股份有限公司第九届董事会第四次会议决议公告

Core Viewpoint - The company has approved the estimated daily related transactions for 2026, amounting to 36 million yuan, based on the actual transactions of 16.846 million yuan from January to November 2025, which does not exceed 5% of the latest audited net assets [5][17]. Group 1: Meeting and Decision - The ninth board meeting was held on December 30, 2025, with all seven directors present, and the proposal for 2026 daily related transactions was approved with a unanimous vote of 5 in favor [1][5]. - The independent directors also reviewed and approved the proposal, confirming it was necessary for the company's operations [2][18]. Group 2: Related Transactions Overview - The estimated total amount for daily related transactions in 2026 is set at 36 million yuan, based on the actual transactions from the previous year [5][17]. - The actual related transactions from January to November 2025 amounted to 16.846 million yuan [5]. Group 3: Related Parties and Relationships - The company holds a 21.74% stake in Zhejiang Zhongke Chuangyue Pharmaceutical Co., Ltd., which is considered a related party due to the company's chairman's position as vice chairman [8][9]. - The company has an indirect 10% stake in Shaoxing Zhaojun Biopharmaceutical Technology Co., Ltd., which is also classified as a related party due to the involvement of a senior executive [11][13]. Group 4: Transaction Purpose and Impact - The daily related transactions with Zhongke Chuangyue and Shaoxing Zhaojun are essential for the company's operational needs and are conducted at market prices, ensuring fairness and transparency [15][17]. - These transactions are expected to enhance the company's competitiveness and will not adversely affect its independence or financial status [17][18].